search
EN
中
Current Location：Home About QyunsCompany Profile

Company Profile

Adhering to the vision of "innovation for the great majority", Qyuns Therapeutics (2509.HK)，as a high-tech enterprise focuses on R&D, industrialization and commercialization of antibody drugs for autoimmune and allergic diseases, and strives to improve drug accessibility and affordability.

Based on our independent innovation capabilities, the company has built a comprehensive pipeline, including 1 product approved by NMPA, 2 products at phase III clinical stage, 4 products at phase II or phase I, with indications covering the four major disease areas of skin, respiratory, digestive, and rheumatism. We are one of the leading companies in China in the field of autoimmune and allergic diseases.  Meanwhile, through the commercialization cooperation with Huadong Medicine and other strategic partners, Qyuns is able to build an integrated layout of the whole industrial chain of R&D, production and sales, and the development certainty is further enhanced.

Qyuns Therapeutics, as a national high-tech enterprise, has applied for more than 100 invention patents domestically and overseas globally. It has also been recognized as a potential unicorn enterprise by Productivity Centre of Jiangsu Province.

Mission

“ To pursue scientific innovation and deliver affordable and quality therapeutics ”

Vision

“ To address unmet needs from patients suffering from autoimmune and allergic diseases and build leadership in those therapeutic areas ”

Values

“ Strive to realize personal value and create social welfare ”

To fulfill this mission and vision, Qyuns adheres to core values, continuously advances research and development processes, and expands product pipelines through continuous innovation, forward-looking industrial layout, and diversified cooperation. To make innovation sustainable, make patients affordable, and make drugs more accessible!

Advantages and Strategies

Our Strengths
01
Exclusive focus on autoimmune and allergic diseases, with comprehensive coverage of four major disease areas of skin, respiratory, digestive, and rheumatism.
02
A diversified pipeline focusing on autoimmune and allergic diseases, with monoclonal antibody pipelines approaching commercialization and a bispecific antibody matrix advancing efficiently through development.
03
Mature commercial-scale production capacity ensures stable and cost-controllable product supply.
04
A pragmatic commercialization model and diversified strategic collaborations continue to enrich Qyuns’cash flow, strengthen its risk resilience, and accelerate product launches.
05
A visionary management team with extensive industry experience and track records of successful entrepreneurship.
Our Strategy
01
Stabilize our core business, with the goal of securing regulatory approval for at least five products and achieving substantial sales volume by 2030.
02
Advance the R&D of bispecific antibody candidates, strategically expand our pipeline to address significant unmet needs in relevant therapeutic areas.
03
Continuously optimize our CMC quality management system, enhance production efficiency, increase capacity utilization, and strengthen our self-sustaining capabilities.
04
Resolutely executing our global expansion strategy: Foster new overseas partnerships and secure strategic collaborations to solidify our growth trajectory.
05
Employee First: Continuously Recruiting and Developing Talent with a Focus on Employee Growth.

Company History

Never stop on innovation and exploration
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015

  • Entered into a collaboration agreement with Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma) with respect to the development , manufacturing and commercialization of QX004N

    Qyuns Successfully Listed on the Main Board of SEHK

    Entered into a collaboration agreement with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”) with respect to the development and commercialization of QX008N

    Received the breakthrough therapy designation for QX005N for the treatment of PN from the CDE

  • Completed Phase III clinical trial for QX001S for the treatment of Ps and BLA accepted

    Completed Phase II clinical trial for QX002N for the treatment of AS and Initiated Phase III clinical trial for QX002N for the treatment of AS

    Initiated Phase II clinical trial for QX005N for the treatment of PN and CRSwNP

    Initiated Phase II clinical trial for QX004N for the treatment of Ps

    Received IND approvals from the NMPA for QX005N for the treatment of COPD and adolescent AD

    Built joint laboratory with China Pharmaceutical University.

    Awarded as a potential unicorn enterprise in Jiangsu Province for four consecutive years

    Won awards from multiple authoritative institutions

  • Won awards from multiple authoritative institutions in the industry.

    Awarded as a potential unicorn enterprise in Jiangsu Province for three consecutive years.

    The Phase III clinical trial of QX001S for the treatment of Ps in China reached its primary endpoint.

    Initiated the Phase II clinical trial of QX002N for the treatment of AS in China and completed patient enrollment.

    Received an IND approval from FDA for QX008N for the treatment of severe asthma.

    Received IND approval from the NMPA for QX008N for the treatment of asthma and for the treatment of moderate-to-severe COPD.

    Received IND approvals from the NMPA for QX005N for the treatment of CSU, the treatment of PN and the treatment of moderate-to-severe asthma.

    Received IND approval from NMPA for QX004 for the treatment of Crohn’s disease.

    Obtained National High tech Enterprise Certificate.

    Closed series C round funding and raised RMB227.5 million.

    Approved to build Jiangsu Provincial Immune Disease Antibody Engineering Research Cente.

  • Completion of shareholding system reform.

    Received IND approval from the NMPA for QX005N for the treatment of CRSwNP.

    Received IND approval from the NMPA for QX006N for the treatment of SLE.

    Received IND approval from the NMPA for QX004N for the treatment of Ps.

    Completed the Phase Ia clinical trial of QX002N for the treatment of AS in China.

    Closed series B++ round funding and raised RMB300 million.

  • Closed series B+ round funding and raised RMB370 million.

    Entered into a collaboration agreement with Zhongmei Huadong with respect to the joint development and commercialization of QX001S in China.

    Closed series B round financing and raised RMB230 million.

    Received IND approval of QX005N from the NMPA for the treatment of moderate-to-severe AD in adults in China.

    Completed the Phase I clinical trial of QX001S for the treatment of Ps in China.

  • Received IND approval of QX002N from the NMPA for the treatment of active AS in adults in China.

  • Cellularforce, our CMC-focused subsidiary, was established in Taizhou.

    Received IND approval of QX001S from the NMPA for the treatment of moderate-to-severe plaque Ps in China.

  • Closed series A round financing and raised RMB120 million.

  • Closed series Pre-A round financing and raised RMB14 million.

    Founded in China Medical City (Taizhou).